{
    "clinical_study": {
        "@rank": "35249", 
        "arm_group": {
            "arm_group_label": "niraparib and temozolomide", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to define the dose-limiting toxicities and maximum tolerated\n      dose of the poly ADP-ribose polymerase inhibitor niraparib and escalating doses of\n      temozolomide in patients with pre-treated incurable Ewing sarcoma."
        }, 
        "brief_title": "ESP1/SARC025 Global Collaboration: A Phase I Study of a Combination of the PARP Inhibitor, Niraparib and Temozolomide in Patients With Previously Treated, Incurable Ewing Sarcoma", 
        "condition": "Ewing Sarcoma", 
        "condition_browse": {
            "mesh_term": [
                "Sarcoma, Ewing's", 
                "Sarcoma"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Histologically confirmed Ewing sarcoma\n\n          -  Evidence of Ewing sarcoma translocation by FISH or RT-PCR.\n\n          -  Must be willing to undergo tumor biopsy at study entry for biologic correlates.\n\n          -  If patient > 18 years, must be willing to undergo on-treatment tumor biopsy unless\n             medically contra-indicated\n\n          -  Recurrent or refractory tumors with no known curative treatment options according to\n             the judgment of the investigator.\n\n          -  Age \u2265 13 years.\n\n          -  Life expectancy of \u2265 3 months.\n\n          -  ECOG performance status 0-2.\n\n          -  Measurable disease on CT or MRI by RECIST 1.1.\n\n          -  Adequate organ function\n\n          -  Patients must have received as a minimum a first line chemotherapy regimen consisting\n             of at least 2 of the following agents:  doxorubicin, cyclophosphamide, ifosfamide,\n             etoposide.\n\n          -  Time elapsed from previous therapy must be \u2265 3 weeks for systemic therapy, \u2265 2 weeks\n             for radiation therapy or major surgery.\n\n          -  Patients who have undergone autologous hematopoietic stem cell transplantation are\n             eligible once they have recovered from all toxicities from therapy\n\n          -  Patients who have received allogeneic hematopoietic stem cell transplantation  will\n             be eligible 6 months after the procedure provided there is no evidence of active\n             graft-versus-host disease and immunosuppressive treatment has been discontinued for\n             at least 30 days.\n\n          -  Patients with central nervous system disease are eligible for enrollment if they have\n             received prior radiotherapy or surgery to sites of central nervous system metastatic\n             disease, have been off glucocorticoids for at least 4 weeks, have no overt evidence\n             of neurological deficit and are \u2265 6 weeks from completion of brain irradiation.\n\n          -  Patients or their legal representative (if the patient is < 18 years old) must be\n             able to read, understand and provide written informed consent to participate in the\n             trial.\n\n          -  Females of childbearing potential as well as males and their partners must agree to\n             use an effective form of contraception during the study and for 6 months following\n             the last dose of study medication.\n\n        Exclusion Criteria:\n\n          -  Clinically significant unrelated illness which would, in the judgment of the treating\n             physician, compromise the patient's ability to tolerate the investigational agent or\n             be likely to interfere with the study procedures or results.\n\n          -  Patients with baseline QTc > 480 msec.\n\n          -  Inability to swallow capsules.\n\n          -  Known hypersensitivity to any of the components of niraparib or prior\n             hypersensitivity reactions to that class of drugs.\n\n          -  Known hypersensitivity reaction to temozolomide or any of its components, or\n             dacarbazine\n\n          -  Concomitant use of any other investigational or anticancer agent(s).\n\n          -  Pregnant patients or patients who are breast feeding. Subjects capable of pregnancy\n             (post menarche and not post-menopausal, defined as over 12 months since final\n             menstrual period) must have a negative pregnancy test within 7 days prior to first\n             dose.\n\n          -  Other clinically significant malignant disease diagnosed within the previous 5 years,\n             excluding intra-epithelial cervical neoplasia or non-melanoma skin cancer.\n\n          -  Active central nervous system disease."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "13 Years"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 21, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02044120", 
            "org_study_id": "ESP1/SARC025"
        }, 
        "intervention": [
            {
                "arm_group_label": "niraparib and temozolomide", 
                "intervention_name": "niraparib", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "niraparib and temozolomide", 
                "intervention_name": "Temozolomide", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Temozolomide", 
                "Dacarbazine"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "May 15, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Bethesda", 
                        "country": "United States", 
                        "state": "Maryland", 
                        "zip": "20892"
                    }, 
                    "name": "National Cancer Institute"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Ann Arbor", 
                        "country": "United States", 
                        "state": "Michigan", 
                        "zip": "48106"
                    }, 
                    "name": "University of Michigan"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "overall_contact": {
            "email": "sarc@sarctrials.org", 
            "last_name": "SARC Office", 
            "phone": "734-930-7600"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "February 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Dose limiting toxicity describes side effects of a drug or other treatment that are serious enough to prevent an increase in dose or level of that treatment.  The maximum tolerated dose is the highest dose of a drug or treatment that does not cause unacceptable side effects.", 
            "measure": "Dose-limiting toxicity and maximum tolerated dose", 
            "safety_issue": "Yes", 
            "time_frame": "Approximately 24 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02044120"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "The percentage of patients whose tumor shrinks or disappears after treatment with niraparib and temozolomide.", 
                "measure": "Tumor response rate of patients treated with niraparib and temozolomide.", 
                "safety_issue": "No", 
                "time_frame": "Approximately 24 months"
            }, 
            {
                "measure": "Progression-free survival at 4 and 6 months of patients treated with niraparib and temozolomide", 
                "safety_issue": "No", 
                "time_frame": "Month 4 and 6"
            }
        ], 
        "source": "Sarcoma Alliance for Research through Collaboration", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Sarcoma Alliance for Research through Collaboration", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}